Crestwood Advisors Group LLC Cuts Holdings in Kenvue Inc. $KVUE

Crestwood Advisors Group LLC cut its holdings in Kenvue Inc. (NYSE:KVUE) by 35.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 928,777 shares of the company’s stock after selling 505,567 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Kenvue were worth $15,074,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KVUE. CWM LLC boosted its position in shares of Kenvue by 6.6% during the 2nd quarter. CWM LLC now owns 31,265 shares of the company’s stock worth $654,000 after purchasing an additional 1,923 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Kenvue by 4.9% in the second quarter. Sequoia Financial Advisors LLC now owns 27,226 shares of the company’s stock valued at $570,000 after purchasing an additional 1,273 shares during the period. Allianz Asset Management GmbH boosted its holdings in Kenvue by 57.6% during the second quarter. Allianz Asset Management GmbH now owns 45,368 shares of the company’s stock worth $950,000 after buying an additional 16,580 shares in the last quarter. Private Trust Co. NA grew its position in Kenvue by 75.6% during the second quarter. Private Trust Co. NA now owns 11,977 shares of the company’s stock worth $251,000 after buying an additional 5,158 shares during the period. Finally, International Assets Investment Management LLC grew its position in Kenvue by 115.5% during the second quarter. International Assets Investment Management LLC now owns 22,082 shares of the company’s stock worth $462,000 after buying an additional 11,835 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.8%

KVUE opened at $18.70 on Tuesday. The firm has a market cap of $35.82 billion, a P/E ratio of 24.93 and a beta of 0.59. The business’s fifty day simple moving average is $17.42 and its 200 day simple moving average is $17.68. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be issued a dividend of $0.2075 per share. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue’s payout ratio is 110.67%.

Analyst Ratings Changes

KVUE has been the topic of several research analyst reports. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Edward Jones downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Johnson Rice reissued a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Barclays raised their price target on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Finally, Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Four analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average price target of $19.46.

Insider Buying and Selling at Kenvue

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of Kenvue stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the purchase, the director owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.